Tango Therapeutics (TNGX) Expected to Post Earnings on Tuesday

Key Points

• Tango Therapeutics is expected to report Q3 2026 results before the market opens Tuesday, November 3. Analysts anticipate a loss of $0.353 per share and revenue of approximately $3.28 million.
• The company previously reported a third-quarter loss of $0.37 per share, missing estimates by $0.05. Analysts project full-year and next-year losses of $1.41 and $1.60 per share, respectively.
• TNGX shares opened at $22.19 and were down 4.9%. Despite recent insider selling and mixed analyst opinions, the stock has a “Moderate Buy” consensus rating and an average price target of $44.62.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) is projected to post its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Tango Therapeutics to post earnings of ($0.3530) per share and revenue of $3.28 million for the quarter. Parties can check the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:00 AM ET.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, analysts expect Tango Therapeutics to post ($1.41) EPS for the current fiscal year and ($1.60) EPS for the next fiscal year.

Tango Therapeutics Trading Down 4.9%

TNGX stock opened at $22.19 on Tuesday. Tango Therapeutics has a fifty-two week low of $7.12 and a fifty-two week high of $34.39. The stock has a fifty day moving average of $23.85 and a 200-day moving average of $21.94.

Insider Activity at Tango Therapeutics

In other news, insider Adam Crystal sold 27,000 shares of Tango Therapeutics stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $24.47, for a total value of $660,690.00. Following the sale, the insider directly owned 115,743 shares in the company, valued at approximately $2,832,231.21. This trade represents a 18.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jessica Newcomb sold 8,200 shares of the business's stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total transaction of $198,604.00. Following the transaction, the insider directly owned 59,121 shares in the company, valued at approximately $1,431,910.62. The trade was a 12.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 6.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on TNGX shares. Guggenheim upped their target price on shares of Tango Therapeutics from $32.00 to $35.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Weiss Ratings upgraded Tango Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Wall Street Zen lowered Tango Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Mizuho boosted their target price on Tango Therapeutics from $36.00 to $40.00 and gave the stock an "outperform" rating in a research report on Friday, July 17th. Finally, HC Wainwright boosted their target price on Tango Therapeutics from $66.00 to $68.00 and gave the stock a "buy" rating in a research report on Tuesday, August 18th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Tango Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $44.62.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango's pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.